Similar articles for PMID: 32444369

Year	Number of Results
2012	1
2013	2
2014	7
2015	6
2016	11
2017	22
2018	29
2019	29
2020	31
2021	36
2022	27
2023	19
2024	16

1

The Prognostic Value of Quantitative Bone SPECT/CT Before ²²³Ra Treatment in Metastatic Castration-Resistant Prostate Cancer.

Dittmann H, Kaltenbach S, Weissinger M, Fiz F, Martus P, Pritzkow M, Kupferschlaeger J, la Fougère C. Dittmann H, et al. J Nucl Med. 2021 Jan;62(1):48-54. doi: 10.2967/jnumed.119.240408. Epub 2020 May 22. J Nucl Med. 2021. PMID: 32444369 Free article.

2

Quantitative assessment of ^99mTc-methylene diphosphonate bone SPECT/CT for assessing bone metastatic burden and its prognostic value in patients with castration-resistant prostate cancers: initial results in a single-center retrospective study.

Oya T, Ichikawa Y, Nakamura S, Tomita Y, Sasaki T, Inoue T, Sakuma H. Oya T, et al. Ann Nucl Med. 2023 Jun;37(6):360-370. doi: 10.1007/s12149-023-01833-0. Epub 2023 Mar 22. Ann Nucl Med. 2023. PMID: 36947324

3

Quantitative bone SPECT/CT: high specificity for identification of prostate cancer bone metastases.

Tabotta F, Jreige M, Schaefer N, Becce F, Prior JO, Nicod Lalonde M. Tabotta F, et al. BMC Musculoskelet Disord. 2019 Dec 26;20(1):619. doi: 10.1186/s12891-019-3001-6. BMC Musculoskelet Disord. 2019. PMID: 31878904 Free PMC article.

4

Review of Palliative ²²³Ra in Metastatic Castration-Resistant Prostate Cancer: Experience at West Virginia University Cancer Center.

Arays R, Ahmad Z, Howard L, Veselicky K, Kolodney J, SijinWen, Hogan T. Arays R, et al. J Nucl Med Technol. 2021 Mar;49(1):70-74. doi: 10.2967/jnmt.120.254474. Epub 2020 Nov 20. J Nucl Med Technol. 2021. PMID: 33219158 Free article.

5

Assessing Radiographic Response to ²²³Ra with an Automated Bone Scan Index in Metastatic Castration-Resistant Prostate Cancer Patients.

Anand A, Trägårdh E, Edenbrandt L, Beckman L, Svensson JH, Thellenberg C, Widmark A, Kindblom J, Ullén A, Bjartell A. Anand A, et al. J Nucl Med. 2020 May;61(5):671-675. doi: 10.2967/jnumed.119.231100. Epub 2019 Oct 4. J Nucl Med. 2020. PMID: 31586004 Free PMC article.

6

More advantages in detecting bone and soft tissue metastases from prostate cancer using ¹⁸F-PSMA PET/CT.

Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE. Pianou NK, et al. Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7. Hell J Nucl Med. 2019. PMID: 30843003 Free article.

7

Prognostic Factors in Patients Treated with 223Ra: The Role of Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT in Predicting Overall Survival.

Etchebehere EC, Araujo JC, Fox PS, Swanston NM, Macapinlac HA, Rohren EM. Etchebehere EC, et al. J Nucl Med. 2015 Aug;56(8):1177-84. doi: 10.2967/jnumed.115.158626. Epub 2015 Jun 11. J Nucl Med. 2015. PMID: 26069307 Free article.

8

²²³Ra Therapy of Advanced Metastatic Castration-Resistant Prostate Cancer: Quantitative Assessment of Skeletal Tumor Burden for Prognostication of Clinical Outcome and Hematologic Toxicity.

Fosbøl MØ, Petersen PM, Kjaer A, Mortensen J. Fosbøl MØ, et al. J Nucl Med. 2018 Apr;59(4):596-602. doi: 10.2967/jnumed.117.195677. Epub 2017 Sep 1. J Nucl Med. 2018. PMID: 28864632 Free article.

9

Baseline ¹⁸F-Fluorocholine PET/CT and bone scan in the outcome prediction of patients treated with radium 223 dichloride.

García Vicente AM, González García B, Amo-Salas M, García Carbonero I, Cassinello Espinosa J, Gómez-Aldaraví Gutierrez JL, Suarez Hinojosa L, Soriano Castrejón Á. García Vicente AM, et al. Clin Transl Oncol. 2019 Mar;21(3):289-297. doi: 10.1007/s12094-018-1920-6. Epub 2018 Jul 13. Clin Transl Oncol. 2019. PMID: 30006674 Clinical Trial.

10

Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study.

Romero-Laorden N, Lorente D, de Velasco G, Lozano R, Herrera B, Puente J, López PP, Medina A, Almagro E, Gonzalez-Billalabeitia E, Villla-Guzman JC, González-Del-Alba A, Borrega P, Laínez N, Fernández-Freire A, Hernández A, Rodriguez-Vida A, Chirivella I, Fernandez-Parra E, López-Campos F, Isabel Pacheco M, Morales-Barrera R, Fernández O, Villatoro R, Luque R, Hernando S, Castellano DC, Castro E, Olmos D. Romero-Laorden N, et al. Eur Urol Oncol. 2024 Jun;7(3):447-455. doi: 10.1016/j.euo.2023.09.015. Epub 2023 Oct 12. Eur Urol Oncol. 2024. PMID: 37838555

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

197 results

Results by year

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Similar articles for PMID: 32444369

197 results

Results by year